OncoMatch/Clinical Trials/NCT06959979
Novel Molecular Targets and Innovative Therapeutic Perspective in Medulloblastoma
Is NCT06959979 recruiting? Yes, currently enrolling (May 2026). This Early Phase 1 trial studies CDK4/6 Inhibitor (Palbociclib, Ribociclib, Abemaciclib) for medulloblastoma, childhood.
Treatment: CDK4/6 Inhibitor (Palbociclib, Ribociclib, Abemaciclib) — Medulloblastoma (MB), a rare yet critical pediatric brain tumor, is divided into 4 molecular subgroups (WNT, SHH, Group 3, Group 4), each with distinct genetic profiles. Despite diagnostic and therapeutic advances, neurotoxicity from standard treatments (resection, radiotherapy, chemotherapy) and the need for long-term care remain challenges. CDK4/6 inhibitors (palbociclib, ribociclib, abemaciclib), approved for breast cancer, show potential in other tumors, but their efficacy in MB is unclear. Treatment resistance is a concern. This project aims to identify genetic markers of sensitivity to CDK4/6 inhibitors in MB, to improve therapies and overcome resistance.
Check if I qualifyExtracted eligibility criteria
Cancer type
Glioblastoma
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify